CSTB

Across TCGA pan-cancer cohorts, CSTB mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated CSTB data layer compared with 25 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CSTB mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CSTB expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

HNSC, LSCC, and CCRCC are the cancer types where CSTB mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Quartile	III,IV	1.000	0.764	.002	36	view →
LSCC	DFS	Median	II,III,IV	1.000	0.829	.003	25	view →
CCRCC	DFS	Median	II,III,IV	0.457	0.818	.007	17	view →
PDAC	OS	Tertile	All	0.496	0.301	.010	15	view →
LUAD	OS	Tertile	All	0.610	0.866	.011	11	view →
GBM	OS	Quartile	All	0.276	0.575	.019	5	view →
UCEC	DFS	Quartile	All	1.000	0.880	.019	4	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

CSTB–HNSC (OS)

Open the HNSC breakdown →